乳腺癌综合辅助放疗后放射性臂丛神经病的风险分析
该回顾性研究纳入498例2004至2012年接受综合辅助放疗的乳腺癌患者,中位随访88个月。所有发生臂丛神经病的常规放疗患者均接受了后腋窝推量照射,未发现明确的剂量学预测因素。
要点
- 综合辅助放疗后放射性臂丛神经病发生率低,常规放疗组1.6%,调强放疗组0.4%。
- 发生臂丛神经病的常规放疗患者均接受后腋窝推量照射,但未发现明确剂量学预测因素。
核心结论
- 放射性臂丛神经病仍是乳腺癌综合辅助放疗的罕见并发症,本研究未发现明确的剂量学预测因素。
- 调强放疗技术似乎不会增加该晚期毒性的发生风险。
研究设计与样本
- 回顾性分析2004至2012年间498例接受综合辅助放疗(照射残余乳腺组织、胸壁及区域淋巴结)的乳腺癌患者。
- 2008年前均采用常规3至5野技术,之后引入调强放疗;通过随访记录判定放射性臂丛神经病事件。
- 将发生放射性臂丛神经病的患者按1:2与常规放疗对照组和调强放疗对照组匹配,进行剂量学分析。
主要发现
- 全队列中位随访88个月,调强放疗队列中位随访92个月。
- 常规放疗组所有发生放射性臂丛神经病的患者均接受了后腋窝推量照射。
- 放射性臂丛神经病患者、常规放疗对照和调强放疗对照的臂丛最大剂量中位值分别为56.0 Gy(范围49.7-65.1)、54.8 Gy(47.4-60.5)和54.8 Gy(54.2-57.3)。
临床怎么用
- 综合辅助放疗后放射性臂丛神经病发生率低,调强放疗未显示增加该风险。
- 对接受后腋窝推量照射的患者应关注臂丛神经病风险,但本研究未确立剂量学阈值。
局限性
- 回顾性研究设计,放射性臂丛神经病事件基于随访记录判定。
- 放射性臂丛神经病事件数少,统计效能有限。
- 常规放疗与调强放疗的年代差异可能引入混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to describe the risk of radiation-induced brachial plexopathy (RIBP) in patients with breast cancer who received comprehensive adjuvant radiation therapy (RT). METHODS AND MATERIALS: Records for 498 patients who received comprehensive adjuvant RT (treatment of any residual breast tissue, the underlying chest wall, and regional nodes) between 2004 and 2012 were retrospectively reviewed. All patients were treated with conventional 3 to 5 field technique (CRT) until 2008, after which intensity modulated RT (IMRT) was introduced. RIBP events were determined by reviewing follow-up documentation from oncologic care providers. Patients with RIBP were matched (1:2) with a control group of patients who received CRT and a group of patients who received IMRT. Dosimetric analyses were performed in these patients to determine whether there were differences in ipsilateral brachial plexus dose distribution between RIBP and control groups. RESULTS: Median study follow-up was 88 months for the overall cohort and 92 months for the IMRT cohort. RIBP occurred in 4 CRT patients (1.6%) and 1 IMRT patient (0.4%) (P = .20). All patients with RIBP in the CRT cohort received a posterior axillary boost. Maximum dose to the brachial plexus in RIBP, CRT control, and IMRT control patients had median values of 56.0 Gy (range, 49.7-65.1), 54.8 Gy (47.4-60.5), and 54.8 Gy (54.2-57.3), respectively. CONCLUSIONS: RIBP remains a rare complication of comprehensive adjuvant breast radiation and no clear dosimetric predictors for RIBP were identified in this study. The IMRT technique does not appear to adversely affect the development of this late toxicity.
引用
- Rudra S, Roy A, Brenneman R, et al. Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation Therapy. Adv Radiat Oncol. 2020. PMID: 33665488. doi:10.1016/j.adro.2020.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。